Abstract: The present invention refers to the use of certain sulfated glycosaminoglycans for treatment or prevention of postpartum haemorrhage. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are administered in combination with at least one uterotonic agent capable of promoting myometrial contractions of the uterus and thereby compress the vessels and cease the bleeding.

Abstract: The present invention refers to the use of certain sulfated glycosaminoglycans for treatment of labor arrest. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are administered in combination with an agent capable of promoting myometrial contractions of the uterus and thereby re-establish effective labor.

Abstract: The present invention refers to the use of certain sulfated glycosaminoglycans for inducing labor. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are used in a combination therapy together with treatment capable of promoting cervical ripening or capable of promoting myometrial contractions of the uterus.

Abstract: A method of treating protracted labor in a pregnant woman comprises administering to a pregnant woman an effective amount of a depolymerized low molecular weight heparin treated with periodate to eradicate antithrombin III binding affinities, thereby exhibiting an anticoagulant activity of 10 BP units/mg or less and an average molecular weight not higher than 10000 Da to prime or curatively treat the cervix and myometrium and for treatment of slow progress of labor. A method for prophylactic priming or curative treatment of the cervix and the myometrium for establishing effective labor in a pregnant woman comprises administering to a pregnant woman an effective amount of a depolymerized low molecular weight heparin as described to prophylactically prime or curatively treat the cervix and myometrium and for establishing effective labor in the pregnant woman.

Abstract: A method of treating protracted labor in a pregnant woman comprises administering to a pregnant woman an effective amount of a depolymerised low molecular weight heparin treated with periodate to eradicate antithrombin III binding affinities, thereby exhibiting an anticoagulant activity of 10 BP units/mg or less and an average molecular weight not higher than 10000 Da to prime or curatively treat the cervix and myometrium and for treatment of slow progress of labor. A method for prophylactic priming or curative treatment of the cervix and the myometrium for establishing effective labor in a pregnant woman comprises administering to a pregnant woman an effective amount of a depolymerised low molecular weight heparin as described to prophylactically prime or curatively treat the cervix and myometrium and for establishing effective labor in the pregnant woman.

Abstract: The invention refers to the use of sulfated glycosaminoglycans having an anticoagulant activity of 100 BP units/mg or less for the manufacture of a pharmaceutical preparation for prophylactic priming or curative treatment of the cervix and the myometrium for establishing effective labor in women.

Abstract: 3-OST-5 proteins, and nucleic acid molecules encoding the same. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed, along with methods of producing each. Isolated and purified antibodies to 3-OST-5 homologs, and methods of producing the same, are also disclosed. 3OST-5 gene products have biological activity in specific heparan sulfate 3-O-sulfotransferase reactions. These reactions provide unique modified heparan sulfate. Thus, therapeutic methods involving this activity are also disclosed.

Abstract: The invention refers to the use of sulfated glycosamino-glycans having an anticoagulant activity of 100 BP units/mg or less for the manufacture of a pharmaceutical preparation for prophylactic priming or curative treatment of the cervix and the myometrium for establishing effective labor in women.

Abstract: The invention refers to the use of sulfated glycosaminoglycans having an anticoagulant activity of 100 BP units/mg or less for the manufacture of a pharmaceutical preparation for prophylactic priming or curative treatment of the cervix and the myometrium for establishing effective labor in women.

Abstract: 3-OST-5 proteins, and nucleic acid molecules encoding the same. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed, along with methods of producing each. Isolated and purified antibodies to 3-OST-5 homologs, and methods of producing the same, are also disclosed. 3OST-5 gene products have biological activity in specific heparan sulfate 3-O-sulfotransferase reactions. These reactions provide unique modified heparan sulfate. Thus, therapeutic methods involving this activity are also disclosed.

Abstract: The invention refers to the use of sulfated glycosaminoglycans having an anticoagulant activity of 100 BP units/mg or less for the manufacture of a pharmaceutical preparation for prophylactic priming or curative treatment of the cervix and the myometrium for establishing effective labor in women.